Colorectal Cancer
Colorectal Cancer
Advertisement
Katy MarshallColorectal Cancer | June 18, 2024
In patients with mismatch repair-deficient colorectal cancer, PD-1 blockade has demonstrated positive benefits.
Read More
Shikha Jain, MD, FACPColorectal Cancer | June 18, 2024
The panel concludes with the challenges of implementing cutting-edge research into colorectal cancer care and practice.
Shikha Jain, MD, FACPColorectal Cancer | June 18, 2024
The panel explores sequencing challenges for therapies like fruquintinib, TAS-102, and sotorasib for colorectal cancer.
Shikha Jain, MD, FACPColorectal Cancer | June 18, 2024
The panel expands on the incorporation of ctDNA in the CRC adjuvant setting, highlighting its prognostic value.
Shikha Jain, MD, FACPColorectal Cancer | June 18, 2024
The panel details strategies for managing oligometastatic CRC, emphasizing the importance of a multidisciplinary approach.
Shikha Jain, MD, FACPColorectal Cancer | June 18, 2024
The panel swaps opinions on advancements in EGFR and KRAS inhibitors, as well as the importance of NGS and liquid biopsy.
Shikha Jain, MD, FACPColorectal Cancer | June 18, 2024
The panel focuses on the evolution of CRC treatment paradigms, including advances in chemo, biologic agents, and more.
Kai-Keen Shiu, MD, PhDColorectal Cancer | June 18, 2024
Kai-Keen Shiu, MD, PhD, continues his discussion on neoadjuvant pembrolizumab for patients with colorectal cancer.
Kai-Keen Shiu, MD, PhDColorectal Cancer | June 18, 2024
Dr. Shiu also discusses how the NEOPRISM-CRC study exceeded its primary endpoint with a high pCR rate.
Erica Barnell, MD, PhDColorectal Cancer | June 15, 2024
Dr. Barnell gives an update on the FDA approval of ColoSense and how the test can aid in public health initiatives.
Cathy Eng, MD, FACP, FASCOColorectal Cancer | June 11, 2024
Dr. Eng comments on how she approaches treatment considerations and management for her younger patients with colon cancer.
Cathy Eng, MD, FACP, FASCOColorectal Cancer | June 11, 2024
Dr. Eng explains how she makes sense of the stage 4 third-line therapy options to administer to her colon cancer patients.
Cathy Eng, MD, FACP, FASCOColorectal Cancer | June 11, 2024
Dr. Eng shares what the COMMIT study suggest about colon cancer and this study's applicability outside of liver metastasis.
Cathy Eng, MD, FACP, FASCOColorectal Cancer | June 11, 2024
Dr. Eng provides her thoughts on ctDNA upfront, sequential, and combined with NGS testing for patients with colon cancer.
Aasma Shaukat, MD, MPHColorectal Cancer | June 6, 2024
Dr. Aasma Shaukat discusses her recent study on the link between advanced adenoma and long-term risk of colorectal cancer.
GI Oncology Now EditorsAdvancements in Oncology | June 6, 2024
The trio delved into the nuances of dosing strategies for TAS-102 and fruquintinib for colorectal cancer, offering insights.
GI Oncology Now EditorsAdvancements in Oncology | June 6, 2024
The trio highlighted the evolution of genetic mutations in colon cancer, pointing to recent studies on NGS.
GI Oncology Now EditorsAdvancements in Oncology | June 6, 2024
Dr. Eng first shared her expertise on the current approaches to treating colon cancer, focusing on the use of ctDNA.
Filippo Pietrantonio, MDASCO 2024: Focus on GI Oncology | June 6, 2024
Drs. Filippo Pietrantonio and Nataliya Uboha continue their conversation with a review of the OS data from CodeBreaK 300.
Benjamin L. Schlechter, MDColorectal Cancer | June 4, 2024
Dr. Schlechter also highlights how this research may effect long-term efficacy and durability of response in patients.
Advertisement
Advertisement
Advertisement
Latest News

June 21, 2024